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More than half of patients with X-linked lympho-proliferative
disease, which is caused by a defect in the intracellular adapter
protein SH2D1A, suffer from an extreme susceptibility to Epstein–
Barr virus. One-third of these patients, however, develop dysgam-
maglobulenemia without an episode of severe mononucleosis.
Here we show that in SH2D1A/ mice, both primary and second-
ary responses of all Ig subclasses are severely impaired in response
to specific antigens. Because germinal centers were absent in
SH2D1A/ mice upon primary immunization, and because
SH2D1A was detectable inwt germinal center B cells, we examined
whether SH2D1A/ B cell functions were impaired. Using the
adoptive cotransfer of B lymphocytes from hapten-primed
SH2D1A/ mice with CD4 T cells from primed wt mice into
irradiated wt mice provided evidence that signal transduction
events controlled by SH2D1A are essential for B cell activities
resulting in antigen specific IgG production. Defects in naı¨ve
SH2D1A/ B cells became evident upon cotransfer with non-
primed wt CD4 cells into Rag2/ recipients. Thus, both defective
T and B cells exist in the absence of SH2D1A, which may explain the
progressive dysgammaglobulinemia in a subset of X-linked lym-
pho-proliferative disease patients without involvement of Ep-
stein–Barr virus.
Epstein–Barr virus  germinal center  immunoglobulin  SLAMCD150
X -linked lymphoproliferative disease (XLP) is a primaryimmunodeficiency that, in more than half of patients, results
in an extreme susceptibility to Epstein–Barr virus (EBV), lead-
ing to fatal infectious mononucleosis or B cell lymphoma (1–6).
XLP patients who are unaffected by an EBV infection develop
dysgammaglobulinemia or agammaglobulinemia even at a very
young age (4, 7–10). SH2D1A, the XLP gene, encodes a single
SH2-domain adapter, which is primarily expressed in T lympho-
cytes and natural killer cells (6, 11–20). SH2D1A binds to a
tyrosine motif in the cytoplasmic tail of six CD150-related
surface receptors (12, 21) and in turn recruits the protein
tyrosine kinase Fyn (16, 17, 22–24). Because the influence of
EBV on B cell responses greatly complicates analyses of dys-
gammaglobulinemia of XLP patients, we examined whether
dysgammaglobulinemia occurs in a mouse in which the XLP
gene SH2D1A (or SAP) has been disrupted (25–28). Upon
infection with the parasites Leishmania major and Toxoplasma
gondii, impaired T helper 2 responses were observed in
SH2D1A/ mice (25–27). Memory antibody responses to lym-
phocytic choriomeningitis virus (LCMV) were impaired, be-
cause SH2D1A/ mice had a severe defect in maintaining
anti-LCMV IgG levels (28).
Here we show that SH2D1A is essential for both T and B cell
responses to soluble T dependent (T-D) antigens. That
SH2D1A-controlled signaling is pivotal in primary Ig responses
is evident from impaired IgM and IgG responses to LCMV and
to the murine Gamma Herpes virus 68 (MHV68), as well as to
well defined protein antigens and haptens. Furthermore, hapten-
specific class switching of all Ig isotypes and germinal center
(GC) formation is defective in SH2D1A/ mice. Using adoptive
transfers of CD4 T cells together with B lymphocytes from
SH2D1A/ mice into Rag2/ or wt recipients, we find that
SH2D1A controls both T and B cell activities.
Materials and Methods
Mice. C57BL6, BALBc, and Rag2/ mice were purchased
from The Jackson Laboratory and were kept under specific
pathogen-free conditions at the Beth Israel Deaconess Medical
Center (BIDMC) Animal Facility. SH2D1A/ C57BL6 and
SH2D1A/ BALBc mice were backcrossed seven times (25).
All animal studies were approved by the BIDMC Institutional
Animal Care and Use Committee.
Quantitation of Serum Ig by ELISA. Isotype-specific Igs were de-
tected and quantitated by ELISA, as described (29).
4-Hydroxy-3-nitrophenylacetyl–Keyhole Lymphocyte Hemocyanin
(NP-KLH)2,4,6,-trinitrophenyl-KLH (TNP-KLH) Immunizations. Mice
were injected i.p. with 300 g of alum-precipitated NP-KLH
(Biosearch). Imject Alum was purchased from Pierce. Mice were
reinjected after 14–21 days with an i.p. injection of 100 g of
NP-KLH in PBS and killed 7 days later. For immunizations with
TNP-KLH (Biosearch), 300 g of alum-precipitated TNP-KLH
plus pertussis toxin (300 ng per mouse) (Calbiochem) was used.
Infection with LCMV or MHV68. C57BL6 SH2D1A-deficient mice
and their wt littermates were infected i.p. with 2  104 plaque-
forming units of the Armstrong strain (ARM) of LCMV-ARM, as
described (25). In other experiments, C57BL6 SH2D1A-deficient
mice and controls were infected with MHV68 (30).
Histology and Immunofluorescence. Snap-frozen spleens in OCT
media were cryosectioned and stained as described (29). Intra-
cellular SH2D1A protein was detected by a combination of two
antibodies: first, a rabbit anti-mouse-SH2D1A antibody
(SH2D1A) was added (12). Subsequently, a Rhodamine-labeled
donkey anti-rabbit IgG was used (Jackson ImmunoResearch).
Adoptive Transfers. CD4 T and B220 B cells were purified from
the spleen of primed or unprimed SH2D1A/ BALBc or wt
BALBc mice by using negative selection, as described (31). Cell
purity was assessed by FACS analysis. Naı¨ve CD4 cells (5 106)
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from SH2D1A/ and wt mice (99% of the cells were CD4,
and1% of the cells were B220) were transferred into Rag2/
mice together with 10 106 SH2D1A/ or wt B cells (cell purity
99%, with 1% of CD4 cells). Mice were then rested for 1
week before standard i.p. immunization with NP-KLH plus
alum. For transfer experiments of hapten-carrier primed cells,
KLH primed and boosted CD4 cells (5  106 cells) of
SH2D1A/ and wt mice were transferred into irradiated wt
recipients (600 rad) together with NP-hen egg lysozyme primed
B cells (10  106) and 100 g of NP-KLH.
Flow Cytometry. Red cell-depleted single-cell suspensions were
stained with fluorescence- or biotin-conjugated antibodies, as
described (25, 29). Cell sorting was performed on a FACSCali-
bur cytometer (Becton Dickinson).
Results
Impaired Primary and Secondary Ig Responses in SH2D1A/ Mice.
Because dysgammaglobulinemia is one of the major manifesta-
tions of XLP (7, 32), we assessed B cell functions and phenotypes
in SH2D1A/ mice in the absence of immunization. Whereas
the basal serum concentrations of IgG1 were lower in
SH2D1A/ C57BL6 mice than in age-matched wt C57BL6
mice kept under specific pathogen-free conditions, the serum
IgG2a concentration was consistently increased during 6 months
(data not shown). Although B cell subsets in bone marrow,
lymph nodes, and spleens of 10-week-old SH2D1A/ and wt
C57BL6 mice were comparable to those of wt mice, the number
of Transitional-2 B lymphocytes (CD21bright IgMbright B220) in
the lymph nodes of SH2D1A/ mice was lower than in wt mice
(Table 1, which is published as supporting information on the
PNAS web site). An increase in the number of CD21-IgM-B220
and CD21-CD23-B220 B lymphocytes was also observed (Ta-
ble 1). Taken together, our results indicate that minor B cell
abnormalities are detectable in nonimmunized SH2D1A/
mice.
Because reduced primary antigen-specific IgM and IgG re-
sponses were detected after infection of SH2D1A/ mice with
LCMV at day 8 (Fig. 1a) or MHV68 (day 15) (Fig. 1b), we also
determined responses to a better-defined antigen. To this end,
we immunized mutant and wt mice with TNP-KLH precipitated
by alum. Although this protocol primarily elicits a Th2 response
and promotes IgG1 production, the serum titers of all TNP-
KLH-specific IgG isotypes and IgM were severely reduced in
SH2D1A/ BALBc mice even 5 days after NP-KLH immuni-
zation (Fig. 1c and data not shown). Similar results were
obtained after immunization of SH2D1A/ C57BL6 mice with
alum-precipitated TNP-KLH (data not shown).
Secondary IgG1, IgG2a, IgG2b, and IgG3 responses to TNP-
KLH were severely impaired in SH2D1A/ BALBc and
C57BL6 mice (Fig. 6, which is published as supporting infor-
mation on the PNAS web site, and data not shown). IgG, IgG1,
and IgG2a serum titers were also significantly reduced in
SH2D1A/ BALBc mice that were immunized with ovalbumin
and Freund’s adjuvant, conditions that do not favor Th2 re-
sponses (data not shown). No defect in T independent antibody
responses was found (data not shown). Thus, SH2D1A/ mice
have a defective early IgM and IgG antigen-specific antibody
response against viruses and T-D antigens.
Requirement of SH2D1A for GC Formation. GCs, the anatomical sites
of T–B cell cooperation (33–35), were almost completely absent
in the spleen of SH2D1A/ mice that had been immunized with
NP-KLHalum (Fig. 7, which is published as supporting infor-
mation on the PNAS web site). Fewer than 2% of the splenic
follicles contained GCs in immunized SH2D1A-deficient ani-
mals, whereas50% of the follicles in identically treated wt mice
contained one or more GC (Fig. 2a). Because of the almost
complete absence of GC formations in immunized SH2D1A/
mice and reports indicating the expression of SH2D1A by human
GC B cells (13, 14, 20, 36, 37), splenic sections of immunized wt
BALBc mice were costained for SH2D1A. Fig. 2b shows that
the SH2D1A protein is expressed by follicular GC B cells. Thus,
an inability to form GCs correlates with defective primary IgM
and IgG antibody responses in the absence of SH2D1A.
Defective B Cell Responses in the Absence of SH2D1A. The observa-
tion that early antibody responses of all isotypes (including IgM) are
impaired in SH2D1A-deficient mice prompted us to focus on a
potential contribution of SH2D1A/ B cells to the impaired
humoral responses in absence of SH2D1A. To this end, carrier-
specific memory CD4 T helper cells were generated by immuni-
zations of SH2D1A/ or wt mice with KLH (Fig. 3a). Hapten-
specific memory B cells were generated by immunization with
NP-hen egg lysozyme. Cotransfer of CD4/ and B/ cells con-
firmed that a functional impairment of CD4/ cells contributes to
defective T-D responses by SH2D1A/ mice (Fig. 3b), and a very
limited NP-specific antibody response was evident upon antigen
recall of recipients reconstituted with B/ cells (Fig. 3b). Thus, the
results of this hapten-carrier experiment show that primed
SH2D1A-deficient B cells are unable to function efficiently in
Fig. 1. Impaired primary antibody responses in SH2D1A/ mice. (a) LCMV-
specific antibody responses in SH2D1A/mice. SH2D1A/ (filled bars) andwt
(open bars) C57BL6 mice were infected with LCMV. LCMV-specific IgM, IgG1,
IgG2a, IgG2b, and IgG3 antibody end-point titers were determined at day 8
after infection, as indicated. y axis, end-point titers (**, P 0.001; n 3; n
number of mice tested per experiment). Results are representative of two
independent experiments. (b) MHV68-specific antibody responses in
SH2D1A/ mice. SH2D1A/ (filled bars) and wt (open bars) C57BL6 mice
were infected with MHV68. MHV68-specific IgM and IgG antibody end-point
titers were determined at day 15 after infection, as indicated. y axis, end-point
titers (**,P0.01; seven SH2D1A/and fourwtmice were tested). (c) Primary
antibody responses to T-D antigens in SH2D1A/ BALBc mice. Primary
TNP-specific antibody titers in the serum of SH2D1A/ BALBc mice (n  4)
were determined 10 days after i.p. immunization with alum-precipitated
TNP-KLH. TNP-specific IgG, IgM, IgG1, IgG2a, IgG2b, and IgG3 antibody titers
of SH2D1A/ (filled bars) andwt (open bars) mice were determined by ELISA.
Serum dilutions start at 1:100; N.D., nondetectable titers (1:100) (y axis 
end-point titers) (**, P  0.001; n  4; n  number of mice tested per
experiment). Results are representative of three independent experiments.
4820  www.pnas.orgcgidoi10.1073pnas.0408681102 Morra et al.
recipient
mice even in the presence of wt primed T helper cells, as
judged by T-D antigen responses. Although this apparent B cell
defect was likely to be cell intrinsic, because the effect was deter-
mined upon adoptive transfer in a wt host, it could not be excluded
that the T cell environment of the donor SH2D1A/ mouse had
permanently affected the donor memory B/ cell. This prompted
us to examine whether naive SH2D1A/ B cells were functionally
impaired by using adoptive transfers of naı¨ve B and T cells. Four
combinations of CD4 and B cells were adoptively transferred into
Rag2/ recipient mice: [CD4/ B/], [CD4/ B/], [CD4/
B/], and [CD4/ B/] (outlined in Fig. 4a). Recipient animals
were immunized with NP-KLH at day 7 after the transfer and were
boosted twice with NP-KLH (Fig. 4a). Seven days after the last
antigen challenge, the [CD4/B/] chimeras had the highest-titer
NP(2)-specific high-affinity antibodies (the number in brackets
indicates the NP:BSA conjugation ratio), whereas the [CD4/
B/] chimeras had the lowest titers (Fig. 4b Left). Consistent with
an intrinsic B cell defect, [CD4/ B/] chimeras almost had no
detectable NP(2)-specific IgG (Fig. 4b Left). As expected, Rag2/
mice reconstituted with [CD4/ B/] cells had intermediate
levels of NP(2)-specific IgG (Fig. 4bLeft). Although the low-affinity
responses by the [CD4/ B/] chimeras were more robust than
their high-affinity antibody response, they were still defective
compared with those of the [CD4/B/] chimeras (Fig. 4bRight).
As judged by the total IgG serum concentrations (Fig. 8, which is
published as supporting information on the PNAS web site),
reconstitution of CD4 and B cells was comparable in all four
chimeras. To examine whether the impaired hapten-specific anti-
body production in the [CD4/ B/] and [CD4/ B/] mice
correlated with defects in the organization of GCs, the spleens of
all four chimeras were stained with anti-CD4, anti-B220, and
peanut agglutinin (PNA). Whereas chimeras that had received
CD4/ and B/ cells had follicular GCs with normal follicular
and T cell areas, [CD4/ B/] chimeras had no GCs (Fig. 4c,
CD4/B/). Importantly, the organization of GCs was disrupted
in [CD4/ B/] chimeras, and large numbers of extrafollicular
PNA cells were detected (Fig. 4c, CD4/ B/). Consistent with
a defect in SH2D1A/T helper cells, [CD4/B/] chimeras had
smaller follicular GCs and an increased relative number of extrafol-
licular PNA-positive cells (Fig. 4c, CD4/ B/). Thus, the pres-
ence of extrafollicular GC B cells, which are known to produce
low-affinity antibodies, might explain low-affinity hapten-specific
responses detected in [CD4/B/] and [CD4/B/] chimeras.
It was conceivable that during the week after transfer into the
Rag2/ recipients, thewt and mutant cells multiplied at a different
rate before immunization. To address this issue, a second set of
adoptive transfer experiments intoRag2/ recipient mice was done
in which the recipient mice received a single immunization at time
of cell transfer (outlined in Fig. 5a). At day 10 after the transfer,
NP-specific IgM antibody responses (Fig. 5b) were defective in the
[CD4/ B/] and [CD4/ B/] chimeras (Fig. 5b Left). Total
IgM serum levels were lower in chimeras reconstituted with B/
cells, when compared with mice reconstituted with B/ cells (Fig.
9a, which is published as supporting information on the PNAS web
site). Furthermore, high- and low-affinity NP-specific IgG antibody
responses at day 10 (Fig. 5b Right; see also Fig. 9b) and at day 20
(data not shown) were markedly lower in [CD4/ B/] and
[CD4/ B/] chimeras than in [CD4/ B/] mice. The IgG
concentrations in the serum of all recipients were comparable (Fig.
9c). Taken together, the early antibody responses to one injection
of antigen given at the day of the adoptive transfer confirm that both
Fig. 2. Follicular GC formation. (a) Reduced number of GC-containing
follicles in the spleens of SH2D1A/ mice. The number of GC-containing
follicles was determined from at least three different consecutive stained
cryosections taken from the spleens of the TNP-KLH mice, described in Fig. 1c.
B cell follicles were identified by anti-CD45RB220-phycoerythrin, and GCs
were stained with PNA-FITC. y axis, percentage of follicles containing one or
more GCs. Filled bar, SH2D1A/ BALBc; open bar, wt BALBc (**, P 0.001;
n 4; n number of mice tested per experiment). Results are representative
of three independent experiments. (b) Expression of the SH2D1A protein in
follicular GCs. Cryosections of the spleen of wt BALBc mice 12 days after
immunization with NP-KLH were stained with immunofluorescent antibodies,
as indicated. Fluorescence was recorded in a Nikon fluorescent microscope. To
detect SH2D1A, acetone-fixed and permeabilized spleen sections were first
stained with a rabbit anti-mouse anti-SH2D1A antibody (SH2D1A). In a second
step, the sections were stained with Rhodamine-labeled donkey anti-rabbit
IgG (red). Shown are FITC-labeled-PNA- (green) identified GCs. (Lower) One of
the few GCs identified on spleens of SH2D1A/ injected mice. Antibodies
used for staining are indicated at the bottom; magnification is indicated at top
right.
Fig. 3. Reduced hapten-specific antibody responses after cotransfers of
primed SH2D1A/ CD4 T cells with wt B cells or primed wt CD4 T cells with
SH2D1A/ B cells into irradiated wt recipient mice. (a) Outline of the exper-
iment. CD4 T cells were purified from the spleens of SH2D1A/BALBc orwt
BALBc mice that had been immunized with KLH attached to alum on day 0 (d
0) and boosted on day 21. B cells were purified from the spleens of SH2D1A/
BALBc or wt BALBc mice that had been immunized 56 days earlier with
NP-hen egg lysozyme (Materials and Methods). The purified CD4 (5 
106recipient) and B cells (10  106recipient) were then cotransferred into
irradiated wt BALBc recipients. At the same time, 100 g of NP-KLH was
injected. Four combinations of CD4 and B cells were used to reconstitute the
irradiated recipients: [CD4/ B/]; [CD4/ B/]; [CD4/ B/] and [CD4/
B/], in which [/] represented SH2D1A/ and [/], wt. Reconstituted
animals were killed and analyzed 7 days after transfer. (b) Hapten-specific
antibody responses. High-affinity NP-specific IgG antibody titers in the serum
of recipient mice (n  4) were determined, as described in Materials and
Methods (n  number of mice tested per experiment). Results are represen-
tative of two independent experiments. Results of ELISAs are shown as fol-
lows: y axis, OD 405 units; x axis, fold dilutions. /, cells derived from
SH2D1A/ mice; /, cells derived from wt mice; open squares, mice recon-
stituted with CD4/ B/ cells; filled squares, mice reconstituted with CD4/
B/ cells; open circles, mice reconstituted with CD4/ B/ cells; filled circles,
mice reconstituted with CD4/ B/ cells.
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B and CD4 T cell defects contribute to severely impaired primary
and secondary humoral immune responses in SH2D1A/ mice.
Discussion
Because dysgammaglobulinemia develops in a subset of XLP
patients without fatal infectious mononucleosis, we hypothesized
that progressively impaired humoral responses might occur in
SH2D1A-deficient individuals and mice, as a consequence of
normal immune insults. Without specific immunization of
SH2D1A/ mice, the levels of serum IgG1 are consistently
lower than in age-matched wt mice, whereas serum IgG2a is
increased (data not shown), and serum IgE is almost undetect-
able (25, 26). Upon exposure to hapten, protein, or viral antigens
(LCMV and MHV68), both primary and secondary humoral
responses, however, are severely impaired in SH2D1A/ mice.
Concomitantly, GC formation and hapten-specific Ig class
switching in SH2D1A/ mice are impaired. Staining of GC with
an anti-SH2D1A antibody shows that the adapter protein is
expressed in a subset of B cells that are present in the GC.
Indeed, using the adoptive transfer of B lymphocytes from
unprimed SH2D1A-deficient mice together with either SH2D1A-
deficient or wt CD4 cells into Rag2/ recipients, we demon-
strate that both SH2D1A/ B and SH2D1A/ CD4 T cells
contribute to defective antigen-specific IgM and IgG production.
Not unexpectedly, these defects are exacerbated upon adoptively
transferring antigen-primed B and T cells. Thus, SH2D1A
controls both CD4 T cell and B cell functions that are impli-
cated in T-D humoral immune responses.
We observed a reduction in primary antibody responses after
infection of SH2D1A/mice with two unrelated viruses, LCMV
and MHV68. Late humoral responses to infection with LCMV
(28) or MHV68 (data not shown) are more severely affected in
SH2D1A/ mice, because these animals fail to generate long-
lived virus-specific plasma cells and memory B cells (28, 38).
Whereas the failure of naive and memory SH2D1A/ CD4
cells to produce IL-4 (refs. 25 and 26 and data not shown) could
Fig. 5. Defective early hapten-specific antibody responses after cotransfer of
naı¨ve SH2D1A/ B cells with naı¨ve wt CD4 cells. (a) Outline of the experiment.
CD4 cells (5  106) together with 10  106 B cells from unprimed SH2D1A/
BALBc or wt BALBc mice were transferred into Rag2/ mice and immunized
withNP-KLHinalumatday0(d0).FourcombinationsofCD4andBcellswereused
to reconstitute the Rag2/ recipients: [CD4/ B/], [CD4/ B/], [CD4/
B/], and [CD4/ B/], in which [/] represented SH2D1A/ and [/], wt.
Serumantibody levels responsesweredeterminedatday10 (d10),andmicewere
killed at day 20 (d 20) for analysis. (b) Analysis of IgM and IgG hapten-specific
antibody responses at day 10. High-affinity [NP(3)-specific] IgM (Left) and IgG
(Right), NP-specific antibody titers in the serum of recipient mice (n  3) were
determined as described in Materials and Methods (n number of mice tested
per experiment). Low-affinity [NP(24)-specific] IgM and IgG NP-specific antibody
titers are shown in Fig. 9b. Results are representative of two independent exper-
iments.ResultsofELISAsare shown(yaxis,OD405units;xaxis, folddilutions)./,
cells derived from SH2D1A/mice;/, cells derived fromwtmice; open squares,
mice reconstituted with CD4/ B/ cells; filled squares, mice reconstituted with
CD4/ B/ cells; open circles, mice reconstituted with CD4/ B/ cells; filled
circles, mice reconstituted with CD4/ B/ cells.
Fig. 4. Defective hapten-specific antibody responses after cotransfer of naı¨ve SH2D1A/ B cells with naı¨ve wt CD4 cells. (a) Outline of the experiment. CD4 cells
(5 106) together with 10 106 B cells from unprimed SH2D1A/ BALBc or wt BALBc mice were transferred into Rag2/ mice at day 0 (d 0). Four combinations
of CD4 and B cells were used to reconstitute theRag2/ recipients: [CD4/B/], [CD4/B/], [CD4/B/], and [CD4/B/], in which [/] represents SH2D1A/
and [/], wt. At day 7 (d 7), mice were immunized with NP-KLH in alum. Reconstituted RAG2/ mice were then boosted twice with NP-KLH (at d 21 and d 28), and
serumantibodylevels responsesweredeterminedatd35. (b)Analysisofhapten-specificantibodyresponses.High- [NP(2)-specific,Left]andlow-affinity [NP(24)-specific,
Right] IgG antibody titers in the serum of recipient mice (n 4) were determined as described inMaterials andMethods (n number of mice tested per experiment).
Results are representative of three independent experiments. Results of ELISAs are shown (y axis, OD 405 units; x axis, fold dilutions)./, cells derived from SH2D1A/
mice;/, cells derived fromwtmice; open squares, mice reconstituted with CD4/B/ cells; filled squares, mice reconstituted with CD4/B/ cells; open circles, mice
reconstituted with CD4/B/ cells; filled circles, mice reconstituted with CD4/B/ cells. (c) Cryosections prepared from the spleens of mice reconstituted with naı¨ve
SH2D1A/ orwtB and CD4 cells (as indicated on the left), 7 days after the last immunization with NP-KLH. Sections were stained with immunofluorescent antibodies,
and fluorescence was recorded in a Nikon fluorescent microscope. Anti-CD45RB220–phycoerythrin (PE) (red) (Left) detects follicle areas (F), anti-CD4-PE (red) (Right)
detects T cell areas (CD4), and PNA-FITC (green) (Left and Right) identifies GC.
4822  www.pnas.orgcgidoi10.1073pnas.0408681102 Morra et al.
in part explain these defective early and late responses, the
underlying cause of the low levels of antigen-specific IgM
responses required further investigation. Obvious T cell-
dependent factors that could have contributed to the
SH2D1A/ phenotype, such as up-regulation of CD40L or
secretion of IL-21 (39), were not impaired in SH2D1A/ mice
(data not shown). We therefore focused first on examining the
possibility of a B cell defect. Our adoptive transfer experiments
indeed demonstrate that SH2D1A is essential for B cell activities
that partake in T cell-dependent IgG and IgM production. The
presence of endogenous wt B cells in the irradiated wt recipients
could readily explain why Crotty et al. (28) did not detect a defect
in SH2D1A/ B cells. Because no endogenous B cells exist in
the Rag2/ recipients used in the current experiments, the
defect in SH2D1A/ B cells could be observed.
The finding that SH2D1A is expressed in a B cell subset is
consistent with the results of the adoptive transfer experiments.
SH2D1A has also been detected in human GC B cells and B cell
tumors (13, 19, 20). EBV-positive Burkitt’s lymphoma lines,
which resemble B cells at the GC stage of differentiation, are
mostly SH2D1A-positive (18). Moreover, a contraction of the
CD19 CD27 B cell memory compartment has been observed
in XLP patients (40). Taken together, the data strongly suggest
that expression of SH2D1A by GC or memory B cells controls
early and memory antibody responses. In the absence of
SH2D1A, the contribution of a small B cell subset to the process
of GC formation is likely to be affected. Because GC B cells
express high levels of the CD95Fas molecule (33), it is tempting
to speculate that the absence of SH2D1A might result in exag-
gerated cell death and inefficient GC formation in SH2D1A/
mice. This notion was indirectly supported by the observation
that the CD150SH2D1A receptor adapter complex modulates
CD95-mediated apoptosis (20). In general, antibody production
by mature B cells outside the GC is intact, and T-independent
responses are normal in the absence of SH2D1A (data not
shown).
Conclusion
The present study unequivocally demonstrates that dysgamma-
globulinemia in SH2D1A-deficient mice takes place in the
absence of a viral infection. This observation is consistent with
dysgammaglobulinemia in XLP patients in the absence of a
detectable infection with EBV or any other virus previously
observed by us and others (4, 7–10). Because SH2D1A controls
signal transduction pathways in both T and B cells initiated by at
least six cell-surface receptors belonging to the CD150 family of
costimulatory adhesion molecules, a dissection of the contribu-
tion of each of these receptors to humoral responses to T-D
antigens will be required for an understanding of the molecular
underpinnings of these biochemical events.
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